Cell line development and upstream process services
Using Cellca cell line development, over 120 projects have been successfully completed.
Zaltrius is a top provider of cell line development services. It offers cost-effective and highly reliable technology platforms. Cellca cell line development consistently delivers clones for stable research cells that have undergone sufficient characterization. From DNA to research cell banks (RCB) in just 14 weeks, it achieves a minimum monoclonal antibody titer of 5g/L with a scalable fed-batch process.
basic information
【Main Elements】 ▪ Cell lines & tests ▪ 4Cell CHO medium system ▪ Expression vector ▪ Upstream process
Price range
Delivery Time
Applications/Examples of results
For more details, please refer to the PDF document or feel free to contact us.
Related Videos
catalog（8）
Download All Catalogs
News about this product（6）
-
Notice of Participation in the Luncheon Seminar at the 4th Annual Meeting of the Japanese Society for Antibody Research
"Next-Generation CHO Cell Line Development Service Integrating AI and Process Intensification - Innovation of Sartorius CLD Workflow" In biopharmaceutical development, establishing high-quality cell lines in a short period has become increasingly important. Sartorius's Cell Line Development (CLD) service has supported the approval of 7 antibody products and over 80 clinical projects to date. Seminar Points: ■ The latest workflow that selects optimal clones by AI analysis of nano-well images and fluorescence data immediately after single-cell cloning with CellCelector ■ A series of CLD processes that continue from Clone Evaluation, quality analysis, scale-up, to technology transfer to CDMO ■ Process Intensification strategies based on High Inoculation Fed-Batch and Perfusion culture ■ Media optimization service that can be used independently (supporting non-GMP prototypes to GMP manufacturing scale) Date and Time: December 3 (Wednesday) 12:20–13:20 Venue: Omiya Sonic City, Exhibition Hall 2
-
Announcement of participation in BioJapan 2025 and presentation at the luncheon seminar.
We will be exhibiting and presenting a luncheon seminar at BioJapan 2025, which will be held at Pacifico Yokohama from October 8 to 10, 2025. At our booth, we will introduce our cell line development services and media optimization services that achieve a scalable fed-batch process with a monoclonal antibody titer of up to 10 g/L in just 9 weeks, from DNA to RCB. We will also showcase single-use culture vessels for process development. In addition, during the luncheon seminar, we will provide a clear overview of Sartorius' CLD services, making it easy to understand for those who are new to the topic. If you are considering shortening timelines, optimizing product quality, or exploring flexible development strategies, please join us. We look forward to seeing you there. Event Overview: October 8 (Wed) - 10 (Fri), 2025, Pacifico Yokohama Exhibition Booth: Small Booth Number D-109 Luncheon Seminar: Title: Minimizing Risks in CHO Cell Line Development through Automation and Predictive Models Seminar Date and Time: October 9 (Thu) 11:30 AM - 12:30 PM
-
I will send you the viewing URL - Flexible and comprehensive services related to CHO cell line development.
Participation in this webinar has ended. If you wish to view it, please contact us. We will send you the URL for the recorded video at a later date. Sartorius has developed CHO cell lines for over 300 projects, with 7 projects approved and more than 80 in clinical trials. The projects include IgG1, 2, 4, multi-specific antibodies, Fc fusion proteins, enzymes, hormones, new drugs, and biosimilars. Our customers range from large companies to startups, with over 70% of them being repeat clients. In this webinar, we will introduce the details of our flexible and comprehensive services, including CHO cell line development, MCB/WCB manufacturing and testing, molecular characterization, FUT8 Knock Out, provision of optimized media, and process enhancement. *We sincerely apologize, but we kindly ask that participants refrain from joining with email addresses other than those from your company or organization. Thank you for your understanding.
-
Announcement of Participation and Seminar Presentation at BioProcess International Asia 2024
This event has ended. We will be exhibiting and presenting at BioProcess International Asia 2024, which will be held in Kyoto from October 21 to 23, 2024. We will introduce Sartorius's cell line development solutions that comprehensively support the commercialization of biopharmaceuticals through products, services, experience, and expertise. 【Event Overview】 Date: October 21 (Monday) 9:00 AM - October 23 (Wednesday) 5:30 PM Location: The Westin Miyako Kyoto *Pre-registration required 【Our Seminar】 Title: Fit for Future: Advancing Bioprocess Manufacturing by Identifying Top Performing Clones and Enhancing Productivity through Process Intensification Seminar Date: October 22 (Tuesday) 9:30 AM
-
[Sending recorded video] Cellca Cell Line Development Technical Update: 9 weeks until RCB
Registration for this webinar has ended. If you wish to view it, please contact us. We will send you the URL for the recorded video at a later date. At Sartorius, we have been providing CHO cell line development services that serve as the foundation for the manufacturing of antibody and protein therapeutics. Two products developed through this service have already been launched, and over 40 molecules are currently in clinical development. This webinar will be divided into two parts to introduce this service. In Part 1, we will present the technical upgrades of this service. In Part 2, we will introduce the media products and related services that have been optimized for this service and are now available for general sale. [Seminar Overview] April 6, 2023 (Thursday) 15:00 (approximately 50 minutes) Webinar recorded broadcast [Japanese, free] *We sincerely apologize, but participation from companies in the same industry and email addresses other than those of your organization is not permitted. Thank you for your understanding.
Recommended products
Distributors
Sartorius Stedim, established in 2007 through the merger of the German company Sartorius, founded in 1870, and the French company Stedim, is a pioneer in "Single-Use Technology (SUT)." As a company capable of providing comprehensive technical support to the pharmaceutical and biotechnology industries, its cutting-edge technology is highly regarded worldwide in the fields of scientific instruments and biotechnology.